Value-based price corridor for bepirovirsen in chronic hepatitis B: an early health technology assessment in a cost-compressed setting. (PubMed, Health Econ Rev) - Oct 22, 2026 - "Bepirovirsen's value-based price is conditional on comparator prices, CET selection, durability of hepatitis B surface antigen (HBsAg) seroclearance, safety, monitoring needs, and cured-state utility assumptions. These eHTA results are hypothesis-generating and should be interpreted within the limits of phase II-derived efficacy inputs, uncertain relapse pathways, and adverse-event and monitoring costs that cannot yet be estimated reliably."
Journal • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Inflammation • Oncology • Solid Tumor
|
|
Bin Wu; Kaijie Yao; Mengxia Yan; Wen Li; Ying Chen; Yun Bao
|